BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World’s First In Vivo Gene Editing Therapy for PH1

  August 22, 2024

   · 

  5 min read
• Press Releases

  Moderna to Host Investor Event - R&D Day and Business Updates

  August 22, 2024

   · 

  1 min read
• Press Releases

  PADCEV® (enfortumab vedotin) in combination with pembrolizumab Approved by Health Canada to Treat Advanced Bladder Cancer

  August 22, 2024

   · 

  5 min read
• Press Releases

  Health Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin

  August 22, 2024

   · 

  7 min read
• Press Releases

  First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

  August 22, 2024

   · 

  6 min read
• 

  Startups

  BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture

  With the help of third-party investors, the new venture will focus on three genetic and rare diseases: tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  BioMarin Brings on Roche, Amgen Alums in Executive Restructuring

  As the biotech implements a more focused strategy for its Roctavian hemophilia A gene therapy, BioMarin has recruited two seasoned pharma executives to bolster its C-suite.

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE

  While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”

  August 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Xcelerate, Inc. Announces Commencement of the Nationalization Process for its PCT International Patent Applications

  August 22, 2024

   · 

  3 min read
• Press Releases

  Avantor® to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

  August 22, 2024

   · 

  1 min read